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Abstract
Background The relationship between visceral obesity and colon cancer outcome has not been well studied. The goal of this
study was to determine the impact of visceral obesity on lymph node (LN) metastasis and overall survival (OS) in colon cancer.
Materials and Methods Metastatic LN ratio (MLR) was defined as the number of involved nodes by tumor divided by the total
number of resected LNs. Visceral (VFA) and subcutaneous fat areas (SFA) were determined by measuring abdominal fat volume
distribution via CT scan, and visceral obesity was defined as a VFA to total fat area ratio (V/T)>0.29.
Results In a multivariate analysis among 186 patients, there were inverse associations between V/T and MLR (OR=0.413, 95 %
CI=0.216–0.789, P=0.007). Furthermore, patients with visceral obesity tended to have significantly better OS than patients with
non-visceral obesity.
Conclusions Higher V/T ratios which indicate referring to visceral obesity was significantly associated with decreasedMLR and
better OS for CRC.
Keywords Obesity . Visceral fat area . Lymph node .
Metastasis . Colon cancer
Introduction
Obesity is an even more prevalent issue in the world, but
comparable data on associations with cancer are lacking.1 In
recent years, obesity has been recognized as one of the possi-
ble non-surgical causes of postoperative adverse events and
longer hospital stay after colorectal surgery.2 Another system-
ic review3 demonstrated that visceral obesity, especially, is
associated with an increased risk of longer hospital stay,
higher morbidity, and longer operative time after colon sur-
gery. However, controversies exist regarding the correlation
between visceral obesity and the outcome of colon cancer
because of inconsistent results among the studies. One of the
most important attributing factors for inconsistent results is the
extent of lymph node (LN) metastasis that is a major determi-
nant for the staging and prognosis of colon cancer and often
guides therapeutic decisions. Especially, wide variations in
number of metastatic LN among recovered LNs after colon
resection exist according to the patient’s anatomy, the biolog-
ical aggressiveness of the tumor, and the surgical
techniques.4,5
In regard to colorectal surgery, visceral obesity contrib-
utes to the technical limitations and is a known predispos-
ing factor for adverse events following surgery. In one
largest cohort study,6 authors show that visceral obesity
was associated with significantly more anastomotic leak-
age, pneumonia, wound infections and reoperations, and
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greater duration of hospital stay. Another study7 evaluated
the importance of LN metastasis in colon cancer found
that visceral obesity was associated with a lower likeli-
hood of metastatic LN involvement because excess fat
may limit accessibility to LNs located deep in the adipose
tissue around major abdominal vessels not included in the
routine en bloc resection.
Although the clinical significance of visceral obesity for
LN involvement is well documented, little has been known
about the real prognosis of colon cancer from visceral obesity
not technical limitation such as inadequate LN dissection.
Therefore, we investigated metastatic LN ratio (MLR), which
is a powerful independent prognostic factor in colon cancer,
even when only a few LN metastases are found,8 not simple
number of LN involvement. MLR can show the quantity of
metastasis to LNs; hence, advanced tumors must have higher
range of MLR.
Because there are few studies that have investigated the
effects of visceral obesity on LN metastasis, a retrospective
study was performed to assess visceral obesity determined by
computed tomography (subcutaneous fat area [SFA], visceral
fat area [VFA], and visceral fat percentage) as a means of
predicting LNmetastasis and overall survival (OS) in a cohort
of subjects with colon cancer.
Materials and Methods
Patients and Study Protocol
This retrospective study was initiated by reviewing the
medical records of patients who underwent a surgical tu-
mor resection due to histologically proven colon cancer in
the Hanyang University Hospital Medical Center between
2003 and 2008. Detailed information was obtained from
the computerized clinical information system, including
demographic information, height and weight, laboratory
findings, pathological findings, and semi-automated as-
sessment of the subcutaneous and visceral fat compart-
ments on multi-detector computed tomography (MDCT).
A total of 278 patients with colon cancer underwent sur-
gical tumor resection with regional lymphadenectomy,
which is dissection of at least the group 1 LNs. In 186
patients with colon cancer, fat measurement was evaluated
with preoperative MDCT and these patients were included
in the study. Based on our exclusion criteria, patients with
limited and palliative resections or those with emergency
surgery for tumor-related complications (hemorrhage, ile-
us, perforation) were not considered for this subgroup.
Furthermore, patients who were diagnosed with histologic
subtypes other than adenocarcinoma (e.g., small cell car-
cinoma or neuroendocrine tumor) were excluded.
Fat Measurement
BMI was calculated as weight divided by height squared.
Patients were divided into four groups based on the National
Institute of Health (NIH) classification for obesity: normal
weight (18.5≤BMI <25), underweight (BMI <18.5), over-
weight (25≤BMI <30) and obese (30≤BMI). Semi-
automated assessment of subcutaneous and visceral fat com-
partments was performed using a dedicated software package
(Fat Assessment Tool, EBW version 4.5, Philips Healthcare).
The transverse cross section at the umbilical level was used to
derive all abdominal fat measurements, as previously de-
scribed and validated.9,10 The vendor-default histogram meth-
od was used, which determines the average attenuation value
(in Hounsfield units) and standard deviation (SD) obtained
from a range of −400 to 0 HU on a selected slice. Fat regions
are then defined as the area enclosed under the fat histogram
curve. Subcutaneous fat is defined as fat that is superficial to
the abdominal wall musculature, whereas visceral fat is deep
in the muscular wall and includes the mesenteric,
subperitoneal, and retroperitoneal components. After the
boundaries for subcutaneous and visceral compartments had
been adjusted at the umbilical level, automated fat segmenta-
tion was performed, which can be further manipulated by the
user to include or exclude focal regions if needed. The pro-
gram then derives the subcutaneous fat area (SFA), the viscer-
al fat area (VFA), total fat area (TFA=SFA+VFA), and the
percentage of visceral fat to total fat area (V/T=VFA/TFA×
100). V/T was calculated to provide a single measure of ab-
dominal fat, as published previously.11,12 Elevated V/T indi-
cated higher visceral fat compared with subcutaneous fat, and
a threshold was set at V/T=29 % to define visceral obesity
(V/T≤29 % indicated subcutaneous obesity (VFs) and V/T>
29 % indicated visceral obesity (VFv)).12,13
Clinicopathologic Data
Individual pathologic data were collected including maximum
tumor diameter (mm), pathologic tumor stage (including T
and N stage), tumor location, degree of tumor differentiation,
and presence of lympho-vascular invasion or peri-neural in-
vasion. In addition, the number of examined LNs, the number
of metastatic LNs, and the metastatic LN ratio (MLR; number
of metastatic LNs/number of examined LNs) was determined
for each patient. LNs were recovered by routine mesenteric
dissection by the pathologist and LN metastases were deter-
mined from subsequent pathologic reports. All pathologic re-
sults including MLR were interpreted by an independent pa-
thologist who had no knowledge of the fat measurement data
or clinical information. Furthermore, the pTand pN categories
were based on the 2002 International Union Against Cancer
and American Joint Committee on Cancer pTNM classifica-
tion (i.e., pTcategory: pT1 [mucosa or submucosa infiltration]
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vs pT2 [muscularis propria] vs pT3 [subserosa or beyond
without other organs involvement] vs pT4 [extension to other
structures or perforates the visceral peritoneum], pN category:
pN0 [no metastasis] vs pN1 [1 to 3 metastatic LNs] vs pN2 [4
or more metastatic LNs]).14 Right-sided colon cancers were
defined as those arising from the cecum to the transverse co-
lon. Left-sided colon cancers were defined as those arising
from the splenic flexure down to and including the recto-
sigmoid junction.15,16
Patient follow-up was conducted until death or the last
contact date. Patient follow-up ended on June 30, 2010 and
the mean follow-up was 45 months. During the follow-up
period, 50 patients died of recurrence or metastasis, and sur-
vival time ranged from 4 to 89 months.
MLR is defined as the number of involved LNs divided by
the number of dissected LNs. TheMLR cutoff was designated
at 18 %. Thus, MLR was categorized as MLR=0 %, MLR<
18 % and MLR≥18 %.17,18 Adjuvant therapy was adminis-
tered according to pathologic stage and physician
recommendation.
Statistical Analysis
Descriptive statistics were provided for binary and continuous
variables using incidence frequency (%) and mean±standard
deviation. The chi-square test was used to compare binary
variables, and two-sample t test was used to compare contin-
uous variables. Multivariate logistic regression analysis ad-
justed by confounding factors was used to assess inter-group
differences in MLR. The Kaplan-Meier model with log-rank
test was used to assess the impact of different characteristics
on survival. Hazard ratios were calculated using the Cox pro-
portional hazard regression model to assess potential predic-
tors of survival. All statistical analyses were performed using
SPSS software for windows, version 17 (SPSS Inc. Chicago,
IL, USA).
Ethics Statement
The study described in this report was approved by the Ethics
Committee of Hanyang University School of Medicine,
Seoul, Korea, in accordance with the Declaration of Helsinki.
Results
Patient Characteristics
Medical records were reviewed for 278 consecutive inpatients
(Fig. 1), all of whom underwent surgical tumor resection with
regional lymphadenectomy (dissection of at least the group 1
LNs). In 186 patients with colon cancer with radical resection,
fat measurement was evaluated by preoperative MDCT. A
total of 92 patients were excluded for the following reasons:
palliative surgery (n=71), emergency surgery for tumor-
related complications (hemorrhage, ileus, perforation) (n=
16), any other pathology except adenocarcinoma (n=3), or
double primary cancer (n=2).
Patients were divided into two groups: VFs (V/T≤29 %,
n=60) and VFv (V/T>29 %, n=126). Table 1 shows the de-
mographic and clinicopathologic characteristics of these two
groups. The mean age of individuals in group VFs was 68.12
±9.16 years old, while the mean in group VFv was 65.43±
11.67 years old. There were slightly more males in both
groups, although this was not significant (60.0 % in group
VFs and 58.7 % in group VFv, P=0.875). Mean BMI in the
VFv group was significantly higher than in the VFs group
(22.72±3.05 vs. 24.21±3.34, P=0.004).
There were no significant differences between the two
groups in terms of the proportion of tumor location (P=
0.872) or maximum tumor diameter (20.12±8.27 vs 19.70±
7.47, respectively; P=0.731). Additionally, the proportion of
pathologic T stage and histologic grade were not statistically
different between the groups. Other pathologic variables in-
cluding lympho-vascular invasion and peri-neural invasion
were similar between the two groups of patients. Furthermore,
although the proportion of MLR was significantly different
between both groups (P<0.001), the mean numbers of re-
trieved LNs were not statistically different between the groups
(26.08±10.27 vs 28.07±15.37, respectively; P=0.298). There
Fig. 1 Flow of patients throughout the study. Medical records were
reviewed for 278 consecutive inpatients, all of whom underwent
surgical tumor resection with regional lymphadenectomy (dissection of
at least the group 1 lymph nodes). In 186 patients with colon cancer with
radical resection, fat measurement was evaluated by preoperativeMDCT.
A total of 92 patients were excluded for the following reasons: palliative
surgery (n=71), emergency surgery for tumor-related complications
(hemorrhage, ileus, perforation) (n=16), any other pathology except
adenocarcinoma (n=3), or double primary cancer (n=2)
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was no significant difference between the two groups in terms
of adjuvant chemotherapy after curative surgery.
Factors Associated with LN Metastasis
Univariate and multivariate logistic regression analysis was
performed to discern the contribution of variable factors on
the LN metastasis, which was categorized as a Bnode
negative^ or Bnode positive.^ Potentially associated variables
for LN metastasis are presented in Table 2. When LN metas-
tasis was the dependent variable in univariate logistic regres-
sion analysis, the following factors were significant: peri-
neural invasion presence (P=0.002) and lower V/T ratio
(P=0.008). In multivariate analysis, LN metastasis was sig-
nificantly associated with peri-neural invasion presence (haz-
ard ratio [HR]=3.621, 95 % confidence interval [CI]=1.686–
7.777, P=0.001) and lower V/T ratio (for higher V/T ratio;
HR=0.291, 95 % CI=0.133–0.638, P=0.002).
Table 1 Baseline characteristics
according to abdominal obesity
classification
Variables VFs (n=060) VFv (n=0126) P
Age 68.12±9.16 65.43±11.67 0.090
Sex (male) 36 (60.0 %) 74 (58.7 %) 0.875
Body mass index (kg/m2) 22.72±3.05 24.21±3.34 0.004
Laboratory findings
HbA1c 6.20±0.63 6.12±1.09 0.595
Total cholesterol 177.58±41.28 173.48±34.90 0.507
Maximum tumor diameter (mm) 20.12±8.27 19.70±7.47 0.731
pT stage
T1 5 (8.3 %) 9 (7.1 %) 0.990
T2 5 (8.3 %) 11 (8.7 %)
T3 44 (73.3 %) 94 (74.6 %)
T4 6 (10.0 %) 12 (9.5 %)
Tumor location
Right side 22 (36.7 %) 49 (38.9 %) 0.872
Left side 38 (63.3 %) 77 (61.1 %)
Histologic grade
Well differentiated 2 (3.3 %) 10 (7.9 %) 0.114
Moderate differentiated 57 (95.0 %) 106 (84.1 %)
Poorly differentiated 1 (1.7 %) 10 (7.9 %)
Lymphatic invasion
Negative 17 (28.3 %) 29 (23.0 %) 0.469
Positive 43 (71.7 %) 97 (77.0 %)
Vascular invasion
Negative 56 (93.3 %) 108 (85.7 %) 0.152
Positive 4 (6.7 %) 18 (14.3 %)
Peri-neural invasion
Negative 34 (56.7 %) 73 (57.9 %) 0.875
Positive 26 (43.3 %) 53 (42.1 %)
No. of retrieved LN 26.08±10.27 28.07±15.37 0.298
MLR
MLR=0 % 14 (23.3 %) 55 (43.7 %) <0.001
MLR<18 % 12 (20.0 %) 50 (39.7 %)
18 %≤MLR 34 (56.7 %) 21 (16.7 %)
Adjuvant CTX 27 (45.0 %) 68 (54.0 %) 0.275
Data were presented as [n (%)] and comparisons were made with chi-square. Data were presented as (mean±SD)
and comparison was made with Student’s t test
VFs subcutaneous obesity as V/T≤29 %, VFv visceral obesity as V/T>29 %, pT stage pathologic T stage, CTX
chemotherapy, RCC right-sided colon cancers arising from the cecum to the transverse colon, LCC left-sided
colon cancers arising from the splenic flexure down to and including the rectosigmoid junction,MLR metastatic
lymph node ratio which is categorized as MLR=0 %, MLR<18 %, and 18 %≤MLR
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Factors Associated with Metastatic LNs Ratio
in Node-Positive Patients
In node-positive patients, univariate and multivariate logistic re-
gression analysis which was categorized as a BMLR<18 %^ or
BMLR≥18 %^ showed that the variables potentially influencing
MLRwere presented in Table 3. WhenMLRwas the dependent
variable in multivariate analysis, MLR was significantly associ-
ated only with lower V/T ratio (for higher V/T ratio; HR=0.111,
95 % CI=0.040–0.307, P<0.001). Furthermore, there was a











≤60 13 (18.8) 31 (26.5) 1 1
>60 56 (81.2) 86 (73.5) 0.644 (0.310–1.336) 0.237 0.560 (0.238–1.316) 0.184
Sex
Male 40 (58.0) 70 (59.8) 1 1
Female 29 (42.0) 47 (40.2) 0.850 (0.583–1.241) 0.401 0.926 (0.506–1.695) 0.803
BMI
Normal 44 (63.8) 79 (67.5) 1 1
Underweight 3 (4.3) 6 (5.1) 1.114 (0.265–4.674) 0.883 1.041 (0.214–5.050) 0.961
Overweight 21 (30.4) 27 (23.1) 0.716 (0.363–1.412) 0.825 0.916 (0.421–1.991) 0.825
Obese 1 (1.4) 5 (4.3) 2.785 (0.315–24.597) 0.357 6.765 (0.662–69.109) 0.107
Tumor location
Rt side colon 24 (34.8) 47 (40.2) 1 1
Lt side colon 45 (65.2) 70 (59.8) 0.794 (0.428–1.474) 0.465 0.884 (0.434–1.793) 0.732
pT stage
T1 6 (8.7) 8 (6.8) 1 1
T2 6 (8.7) 10 (8.5) 1.250 (0.289–5.407) 0.765 1.862 (0.336–10.308) 0.477
T3 52 (75.4) 86 (73.5) 1.240 (0.408–3.775) 0.704 1.167 (0.272–5.009) 0.835
T4 5 (7.2) 13 (11.1) 1.950 (0.445–8.548) 0.376 1.671 (0.267–10.455) 0.583
Histology
Well diff 3 (4.3) 9 (7.7) 1 1
Moderate diff 65 (94.2) 98 (83.8) 0.503 (0.131–1.926) 0.098 0.273 (0.059–1.272) 0.098
Poorly diff 1 (1.4) 10 (8.5) 3.333 (0.292–38.082) 0.333 2.623 (0.184–37.469) 0.477
Lymphatic inv
Absent 19 (27.5) 27 (23.1) 1 1
Present 50 (72.5) 90 (76.9) 1.267 (0.641–2.503) 0.496 1.084 (0.435–2.701) 0.862
Vascular inv
Absent 60 (87.0) 104 (88.9) 1 1
Present 9 (13.0) 13 (11.1) 0.833 (0.336–2.065) 0.694 0.582 (0.186–1.820) 0.352
PNI
Absent 50 (72.5) 57 (48.7) 1 1
Present 19 (27.5) 60 (51.3) 2.770 (1.460–5.257) 0.002 3.621 (1.686–7.777) 0.001
V/Ta
≤29 % 14 (20.3) 46 (39.3) 1 1
>29 % 55 (79.7) 71 (60.7) 0.393 (0.196–0.787) 0.008 0.291 (0.133–0.638) 0.002
BNode negative^ is defined as group that no metastatic lymph nodes were retrieved in. BNode positive^ is defined as group that at least one or more
metastatic lymph nodes were retrieved in
BMI body mass index, Rt right, Lt left, pT stage pathologic T stage, diff differentiated, inv invasion, PNI perineural invasion, V/T the percentage of
visceral fat to total fat area
a Elevated V/T indicated higher visceral fat compared with subcutaneous fat, and a threshold was set at V/T=29% to define visceral obesity (V/T≤29%
indicated subcutaneous obesity and V/T>29 % indicated visceral obesity)
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marginal significance regarding with tumor location (for left side
colon cancer; HR=2.531, 95 % CI=0.963–6.653, P=0.060).
Survival Analysis
A Kaplan-Meier model was used to estimate survival
probability of OS stratified by V/T classification for the
186 study participants. Median OS had not been reached
for any of the subgroups at the end of follow-up. Mean
OS was 69.71±3.97 months in the VFs subgroup vs
80.02±2.17 months in the VFv subgroup. Patients with
visceral obesity tended to have better OS than non-
visceral obesity patients with marginal significance (P=
0.057) (Fig. 2).











≤60 15 (24.2) 16 (29.1) 1 1
>60 47 (75.8) 39 (70.9) 0.778 (0.342–1.771) 0.550 0.561 (0.194–1.623) 0.286
Sex
Male 36 (58.1) 34 (61.8) 1 1
Female 26 (41.9) 21 (38.2) 0.855 (0.407–1.796) 0.679 0.972 (0.380–2.488) 0.954
BMI
Normal 39 (62.9) 40 (72.7) 1 1
Underweight 2 (3.2) 4 (7.3) 1.950 (0.338–11.264) 0.883 1.407 (0.132–15.061) 0.778
Overweight 16 (25.8) 11 (20.0) 0.670 (0.277–1.625) 0.825 0.693 (0.229–2.096) 0.516
Obese 5 (8.1) 0
Tumor location
Rt side colon 29 (46.8) 18 (32.7) 1 1
Lt side colon 33 (53.2) 37 (67.3) 1.806 (0.851–3.833) 0.465 2.531 (0.963–6.653) 0.060
pT stage
T1 3 (4.8) 5 (9.1) 1 1
T2 7 (11.3) 3 (5.5) 0.257 (0.036–1.843) 0.176 0.494 (0.044–5.497) 0.566
T3 47 (75.8) 39 (70.9) 0.498 (0.112–2.216) 0.360 1.969 (0.216–17.946) 0.548
T4 5 (8.1) 8 (14.5) 0.960 (0.156–5.900) 0.965 8.671 (0.540–139.347) 0.127
Histology
Well diff 4 (6.5) 5 (9.1) 1 1
Moderate diff 52 (83.9) 46 (83.6) 0.708 (0.179–2.794) 0.622 0.327 (0.059–1.810) 0.200
Poorly diff 6 (9.7) 4 (7.3) 0.533 (0.086–3.307) 0.500 0.549 (0.057–5.257) 0.603
Lymphatic inv
Absent 12 (19.4) 15 (27.3) 1 1
Present 50 (80.6) 40 (72.7) 0.640 (0.269–1.521) 0.312 0.324 (0.074–1.413) 0.134
Vascular inv
Absent 53 (85.5) 51 (92.7) 1 1
Present 9 (14.5) 4 (7.3) 0.462 (0.134–1.594) 0.222 0.253 (0.040–1.593) 0.143
PNI
Absent 29 (46.8) 28 (50.9) 1 1
Present 33 (53.2) 27 (49.1) 0.847 (0.410–1.753) 0.655 1.517 (0.521–4.416) 0.445
V/Ta
≤29 % 12 (19.4) 34 (61.8) 1 1
>29 % 50 (80.6) 21 (38.2) 0.148 (0.064–0.341) <0.001 0.111 (0.040–0.307) <0.001
BMI body mass index, Rt right, Lt left, pT stage pathologic T stage, diff differentiated, inv invasion, PNI perineural invasion, V/T the percentage of
visceral fat to total fat area,MLRmetastatic lymph node ratio whichwas defined as the number of involved nodes by tumor divided to the total number of
resected lymph nodes and categorized as MLR<18 % and 18 %≤MLR
aElevated V/T indicated higher visceral fat compared with subcutaneous fat, and a threshold was set at V/T=29% to define visceral obesity (V/T≤29%
indicated subcutaneous obesity and V/T>29 % indicated visceral obesity)
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Discussion
This is the first report to use multiple quantitative visceral fat
measurements (SFA, VFA, and TFA) to examine the associa-
tions between visceral obesity and LN metastasis or OS in
patients with curative resection for colon cancer. The primary
findings showed significant positive associations between
MLR of colon cancer and peri-neural invasion. Also, there
was a significant inverse association between MLR and vis-
ceral obesity. Many recent reports on colon cancer demon-
strated that obese patients generally have lower chances of
survival and more aggressive biological tumor features. One
systematic review and meta-analysis3 of 1230 patients among
nine studies reported that visceral obesity leads to a longer
hospital stay, higher morbidity, and longer operative time after
elective colon surgery. Furthermore, four of nine studies re-
ported that LN retrieval was significantly lower in the visceral
obese patients and overall outcome including survival was
poorer than non-obese patients because of incomplete LN
dissection.
Interestingly, our results demonstrated that BMI was not
associated with overall outcome of colon cancer including
LNmetastasis or OS. In clinical practice, many studies have
been used anthropometric index such as BMI,WC, or waist-
to-hip ratio as surrogates of visceral obesity.19,20 However,
according to one study, authors demonstrated that BMI is
not an accurate index to quantify intra-abdominal visceral
fat because of the different fat tissue distribution between
individuals and various ethnic groups.21 Furthermore, one
study22 tested the correlation between BMI and visceral
obesity concluded that there was a weak positive correlation
between BMI and VFA and no correlation between BMI and
the VFA/SFA ratio. These results indicate that BMI alone is
not an accurate index of visceral obesity. This suggests that
VFA/SFA ratio is a more accurate index of visceral obesity
than VFA alone or other anthropometric indices, as the latter
also depends on patient size and not exclusively on distri-
bution of adipose tissue. Interestingly, in colon cancer pa-
tients in this study, 67.7 % met the criteria for visceral obe-
sity by V/T and only 3.2 % of patients had a BMI≥30.
A previous study7 evaluated the importance of LN metas-
tasis as a determinant of colon cancer patient prognosis and
found that being overweight was associated with a lower like-
lihood of metastatic LN involvement. In a large intergroup
trial (INT-0089), incomplete lymphadenectomy of various ex-
tents was attributed to limitation accessibility to LN located
deep in the excess fat tissue around major vessels.23 This
study emphasized the importance of the stage migration phe-
nomenon and poorer prognoses related to inadequate LN dis-
section. In addition, if a patient was classified as node-nega-
tive, survival was also affected positively with an increase in
the number of nodes analyzed; this observation has important
clinical implications for surgeons operating on obese individ-
uals. There is some debate over the number of nodes that must
be examined to yield a reliable assessment of patient nodal
status. In 1990, the Working Party Report to the World Con-
gresses of Gastroenterology reviewed this topic and came to a
consensus recommendation that at least 12 nodes must be
sampled to adequately stage a patient.24 However, a study
by Goldstein et al.25 found that the number of node-positive
patients continued to increase until 17–20 nodes had been
examined, leading to the conclusion that a minimum of 17
nodes should be analyzed. Similarly, Wong et al.26 found that
significantly fewer nodes were examined in node-negative
patients than in node-positive patients (14 vs 20 nodes), and
to achieve a nodal positivity rate commensurate with the Na-
tional Cancer Data Bank, at least 14 nodes should be exam-
ined. It is clear that to accurately stage a patient with colon
cancer, it is best to evaluate as many nodes as possible. The
number of LNs dissected in the current study ranged from 12
to 90, with a mean of 27.4 (26.08±10.27 in VFs group vs
28.07±15.37 in VFv group, P=0.298). No patient had fewer
than the required 12 nodes dissected.
However, in terms of statistics, the number of metastatic
LNs increases according to the number of dissected nodes,
suggesting that the pathologic N stage can be influenced by
the extent of lymphadenectomy. In addition, the pathologic N
stage may be changed by adding or reducing one positive LN,
suggesting that colon cancer classified as N1 after limited LN
dissection may be classified as N2 after extensive lymphade-
nectomy. Therefore, Chen et al.27compared the prognostic
values of the MLR categories with that of the pathologic N
(pN) categories in patients with no less than 12 LNs retrieved.
Multivariate analysis showed that both MLR and LN involve-
ment were independent prognostic factors. They proposed that
Fig. 2 Survival curves in patients according to abdominal obesity
classification. Kaplan-Meier model estimates of survival probability
according to V/T classification for the 186 study participants. Mean OS
was 69.71±3.97 months in the VFs subgroup vs 80.02±2.17 months in
the VFv subgroup. Patients with visceral obesity tended to have better OS
than non-visceral obesity patients with marginal significance (log-rank
test: V/T≤29 % (VFs) vs 29 %<V/T (VFv), P=0.057) (red line, VFv;
blue line, VFs)
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MLR categories had better prognostic value than pN catego-
ries because the MLR categories had a higher hazard ratio
than the pN categories. Another study by Schumacher et al.17-
compared the pathologic N stage with a classification based
on MLR in patients who underwent curative tumor resection
and determined that MLR is the most important prognostic
factor for colon cancer. Based on this theoretical background,
the present study used MLR as a more accurate prognostic
value compared to traditional classification of LN metastasis
in the TNM staging system.
In a Kaplan-Meier model with log-rank test between VFs
group and VFv group, no differences were observed in overall
survival rate, although MLR was significantly lower among
patients with visceral obesity (VFv group). This lack of sur-
vival benefits might be related to differences in various con-
founding factors (e.g., regimen of the postoperative adjuvant
chemotherapy or any other patient-related factors).
The limitations of this study include its retrospective de-
sign, which is subject to incomplete data and potential se-
lection bias. Moreover, the use of visceral obesity as a risk
stratification tool has its own disadvantages. First, an ac-
cepted V/T threshold for defining visceral obesity is cur-
rently lacking. Furthermore, accurate measurement of vis-
ceral obesity relies on CT imaging, which is expensive and
impractical in everyday clinical practice. Other confound-
ing factors that were not considered may have had an effect
on the LN metastasis and OS. Especially, the lack of surviv-
al benefits observed in this study could be attributed to the
confounding factors that were not considered such as adju-
vant chemotherapy or adjusting for many baseline con-
founding factors that may dilute a potential survival benefit.
Finally, this study did not analyze the disease-free survival
rate or the loco-regional recurrence rate, for which LN me-
tastasis is a very important independent risk factor in pa-
tients with colon cancer after curative resection.
Conclusion
We found that a higher ratio of visceral fat was associated with
a decreased LN metastasis or MLR, although there was no
association between visceral obesity and overall survival for
colon cancer. This was labeled the Bbuffering effect^ and the
underlying mechanism is still unknown. Further studies about
MLR and local or systemic recurrence rates are warranted to
clarify the association between survival rates and visceral fat
distribution in colon cancer.
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